HLA-B*1502 & B2M

HLA-B*1502 & B2M Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag & Avi Tag (1)

  • Conjugate

    Biotin-labeled (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
HLM-H82Eq
Human
HEK293
Biotinylated Human HLA-B*15:02&B2M Monomer Protein (Peptide free, MALS verified)
Total: 1
  • 1

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
IPP-204106N6L; Nucant-6L; IPP-204106; IPP-204106N; poyplexed IPP-204106Phase 2 ClinicalImmupharma PlcSolid tumours; Neoplasms
Details
AS-1411AGRO-100; GR-026-B; AS-1411; ACT-GRO-777Phase 2 ClinicalUniversity Of Louisville, Antisoma, University Of Alabama At BirminghamSolid tumours; Neoplasms
Details
Pegylated recombinant human endostatin (Tsinghua University)M-2ES; CRB-0401Phase 1 ClinicalTsinghua University, Beijing Protgen Biotechnology Development Co Ltd, Beijing Proji Pharmaceutical Technology Co LtdSolid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
APTA-16APTA-16; SJP1604Phase 1 ClinicalAptabio Therapeutics IncLiver Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Recombinant human endostatin (Simcere)YH-16ApprovedJiangsu Simcere Pharmaceutical Co LtdEndostar, 恩度, EnduMainland ChinaCarcinoma, Non-Small-Cell LungShandong Simcere Bio-Pharmaceutical Co Ltd2005-09-12Head and Neck Neoplasms; Esophageal Neoplasms; Ascites; Osteosarcoma; Nasopharyngeal Carcinoma; Brain metastases; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information